Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps1-02-02 | Graves’ Disease | ETA2023

Predetermined vs calculated 131I activity for the treatment of patients with graves’ disease: which is the best?

Arcidiacono Francesco , Barca Ignazio , Prinzi Antonio , Scuto Andrea , Volpe Salvatore , Piticchio Tommaso , Malandrino Pasqualino , Frasca Francesco , Belfiore Antonino

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...

ea0092op-10-03 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

KI67 proliferative index, but not mitotic count and necrosis, is a prognostic factor in patients with medullary thyroid cancer: a single-center retrospective analysis according to the 2022 who pathological classification

Prinzi Antonio , Bosco Agata , Mirone Alessandro , Tumino Dario , Di Benedetto Guenda , Gambero Federica , Bartoloni Giovanni , Frasca Francesco , Belfiore Antonino , Malandrino Pasqualino

Background: The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors has introduced, as other neuroendocrine neoplasms, new pathological features to classify medullary thyroid carcinoma (MTC) in low/high grade. However, whether it can be reliable in clinical practice should be confirm by further studies.Aim: To verify the predictive value of the 2022 WHO grading system in patients with MTC.Materials and Methods: Tumor tis...